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Summary
Background—Sleep-disordered breathing is associated with major morbidity and mortality. 
However, its prevalence has mainly been selectively studied in populations at risk for sleep-
disordered breathing or cardiovascular diseases. Taking into account improvements in recording 
techniques and new criteria used to define respiratory events, we aimed to assess the prevalence of 
sleep-disordered breathing and associated clinical features in a large population-based sample.
Methods—Between Sept 1, 2009, and June 30, 2013, we did a population-based study 
(HypnoLaus) in Lausanne, Switzerland. We invited a cohort of 3043 consecutive participants of 
the CoLaus/PsyCoLaus study to take part. Polysomnography data from 2121 people were included 
in the final analysis. 1024 (48%) participants were men, with a median age of 57 years (IQR 49–
68, range 40–85) and mean body-mass index (BMI) of 25·6 kg/m2 (SD 4·1). Participants 
underwent complete polysomnographic recordings at home and had extensive phenotyping for 
diabetes, hypertension, metabolic syndrome, and depression. The primary outcome was 
prevalence of sleep-disordered breathing, assessed by the apnoea-hypopnoea index.
Findings—The median apnoea-hypopnoea index was 6·9 events per h (IQR 2·7–14·1) in women 
and 14·9 per h (7·2–27·1) in men. The prevalence of moderate-to-severe sleep-disordered 
breathing (≥15 events per h) was 23·4% (95% CI 20·9–26·0) in women and 49·7% (46·6–52·8) in 
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men. After multivariable adjustment, the upper quartile for the apnoea-hypopnoea index (>20·6 
events per h) was associated independently with the presence of hypertension (odds ratio 1·60, 
95% CI 1·14–2·26; p=0·0292 for trend across severity quartiles), diabetes (2·00, 1·05–3·99; 
p=0·0467), metabolic syndrome (2·80, 1·86–4·29; p<0·0001), and depression (1·92, 1·01–3·64; 
p=0·0292).
Interpretation—The high prevalence of sleep-disordered breathing recorded in our population-
based sample might be attributable to the increased sensitivity of current recording techniques and 
scoring criteria. These results suggest that sleep-disordered breathing is highly prevalent, with 
important public health outcomes, and that the definition of the disorder should be revised.
Funding—Faculty of Biology and Medicine of Lausanne, Lausanne University Hospital, Swiss 
National Science Foundation, Leenaards Foundation, GlaxoSmithKline, Ligue Pulmonaire 
Vaudoise.
Introduction
Sleep-disordered breathing is a chronic disorder caused by repeated upper-airway collapse 
during sleep, resulting in recurrent nocturnal asphyxia, fragmented sleep, major fluctuations 
in blood pressure, and increased sympathetic nervous system activity.1 Furthermore, patients 
with untreated sleep-disordered breathing are at increased risk of hypertension, stroke, heart 
failure, diabetes, car accidents, and depression.2–9 Polysomnography is the gold standard to 
diagnose sleep-disordered breathing. However, despite the important effect of sleep-
disordered breathing on public health, only a few attempts have been made to screen the 
general population for this disorder using polysomnography. In the late 1980s and early 
1990s, three large cohort studies were done in the USA: the Wisconsin Sleep Cohort 
Study,10 the Sleep Heart Health Study,11 and the Penn State Cohort.12 From these studies, 
the prevalence of sleep-disordered breathing—defined by an apnoea-hypopnoea index 
greater than five events per h—was estimated to be between 6·5% and 9% in women and 
between 17% and 31% in men.10,12 However, this prevalence has since been revised to 
around 34% in men aged 30–70 years and 17% in women aged 30–70 years.13 Although 
these studies provide important epidemiological data, they included an enriched selection of 
people at risk for sleep-disordered breathing (based on questionnaires) or cardiovascular 
disease. Therefore, the prevalence of sleep-disordered breathing could not be measured 
directly but was estimated through complex statistical calculations with reference to other 
population-based studies.
Researchers on subsequent epidemiological studies have either selected specific ethnic 
groups14,15 or high-risk populations.16 To record nocturnal breathing, all except a few13,17 
used less sensitive technology (eg, pen and paper recorders, thermocouples, or respiratory 
inductive plethysmography)16,18 than nasal pressure technology, which is now the standard 
of care. Furthermore, pulse oximeters have improved considerably over the years. Both 
technical developments have increased sensitivity for diagnosis of sleep-disordered 
breathing. Moreover, the American Academy of Sleep Medicine (AASM) has revised 
criteria used to define nocturnal respiratory events.19–21 Because most clinical settings now 
use recording techniques with increased sensitivity and the new definitions for respiratory 
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events, the prevalence of sleep-disordered breathing and its association with important 
health outcomes needs to be revisited.
We designed the HypnoLaus Sleep Cohort study to assess the prevalence of sleep-
disordered breathing using state-of-the-art polysomnographic recording techniques and 
updated definitions in a general unselected population. Furthermore, the clinical relevance of 
the revised definition of sleep-disordered breathing was also investigated by examining its 
associations with cardiovascular, metabolic, and psychiatric comorbidities.
Methods
Participants
We selected participants for our study from individuals included in the population-based 
CoLaus/PsyCoLaus cohort study, described previously.22,23 Briefly, the CoLaus/PsyCoLaus 
study was undertaken between 2003 and 2006 and included a sample of 6733 people aged 
35–75 years, who were selected at random (using Stata version 9.1) from the population 
register of the city of Lausanne, Switzerland (altitude approximately 490 m).22 The 
distribution of age groups, sex, and postal codes in CoLaus/PsyCoLaus participants was 
representative of the source population.22 The original aim of the CoLaus/PsyCoLaus cohort 
study was to investigate the prevalence of cardiovascular risk factors and psychiatric 
disorders in the general population and to identify genetic determinants and mechanisms 
involved in their association.
At 5-year follow-up of the CoLaus/PsyCoLaus cohort (in 2009–12), individuals who were 
willing to return underwent a second physical (n=5064) and psychiatric (n=4001) 
examination and were given questionnaires by trained interviewers. These assessments 
included questions on their demographic, medical, and treatment history, and smoking and 
alcohol consumption. Sleep-related complaints and habits were investigated using the 
Pittsburgh sleep quality index, the Epworth sleepiness scale, and the Berlin questionnaire for 
sleep-disordered breathing. Blood samples were taken in the fasting state and a large panel 
of biological variables was measured.24 Selection of participants for the HypnoLaus Sleep 
Cohort study was consecutive and not based on responses to the questionnaires; 
investigators were unaware of the results of the questionnaires.
The ethics committee of the University of Lausanne approved the CoLaus/PsyCoLaus 
cohort study and the HypnoLaus Sleep Cohort study. We obtained written informed consent 
from all participants.
Procedures
Polysomnography was done by certified technicians to assess the prevalence of sleep-
disordered breathing. They equipped participants with a polysomnographic recorder 
(Titanium, Embla Flaga, Reykjavik, Iceland) between 1700 h and 2000 h at the Center for 
Investigation and Research in Sleep at the University Hospital of Lausanne. All sleep 
recordings took place in the patients’ home environment in accordance with 2007 AASM 
recommended setup specifications.19 We recorded breathing using nasal pressure sensors. 
Heinzer et al. Page 3
Lancet Respir Med. Author manuscript; available in PMC 2015 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
We asked individuals who were currently receiving treatment for sleep-disordered breathing 
(n=38) to discontinue their treatment 1 week before the sleep recording.
Two trained sleep technicians (DA and NT) who were unaware of the results of the previous 
questionnaires scored polysomnographic recordings manually using Somnologica software 
(version 5.1.1, Embla Flaga, Reykjavik, Iceland). An expert sleep clinician (JH-R) reviewed 
every recording and a second sleep expert (RH) did random quality checks. Quality control 
for concordance between the two polysomnography scorers was implemented periodically to 
ensure that both technicians achieved at least 90% agreement for sleep stages and respiratory 
events and an 85% level of agreement for arousals.25 We scored sleep stages and arousals 
according to 2007 AASM recommendations.19 We defined apnoea as a drop of at least 90% 
of airflow from baseline lasting 10 s or longer. We initially scored hypopnoea events using 
1999 AASM Chicago criteria,20 but all recordings were rescored using the more restrictive 
2007 AASM criteria19 and the more liberal 2012 AASM criteria21 (≥30% drop of airflow 
lasting at least 10 s with either an arousal or ≥3% oxygen saturation drop). We used the 
2012 criteria for our analysis (because they are the most recent and currently recommended 
criteria) and reported the average number of apnoea and hypopnoea events per h of sleep 
(the apnoea-hypopnoea index). We defined sleep-disordered breathing with usual clinical 
thresholds (ie, no sleep-disordered breathing, <5 events per h; mild, ≥5 to <15 events per h; 
moderate, ≥15 to <30 events per h; and severe, ≥30 events per h). The appendix (p 4) shows 
apnoea-hypopnoea index scores using 1999 and 2007 criteria.19,20 We defined excessive 
daytime sleepiness as an Epworth score greater than ten (maximum score 24).
We did various clinical tests before polysomnography to investigate the association of sleep-
disordered breathing with cardiovascular, metabolic, and psychiatric comorbidities. We 
measured blood pressure three times on the left arm and calculated the average of the last 
two readings. We defined arterial hypertension as either systolic blood pressure of 140 mm 
Hg or higher, diastolic blood pressure of 90 mm Hg or higher, or current use of 
antihypertensive drugs. We calculated the waist-to-hip ratio as the ratio of the circumference 
of the waist to that of the hip, as recommended by WHO. We measured neck circumference 
between the mid-cervical spine and the mid-anterior neck, just below the laryngeal 
prominence, if palpable. We obtained a fasting blood sample for various analyses, including 
measurement of glucose concentration and lipids. We defined diabetes as either fasting 
blood glucose of 7 mmol/L or higher or current drug treatment for diabetes. We defined 
metabolic syndrome according to the Adult Treatment Panel III (ATP-III) report.26 
Participants self-reported their alcohol drinking habits and the number of alcoholic drinks 
taken during the evening preceding the polysomnographic recording. We used the semi-
structured Diagnostic Interview for Genetic Studies to diagnose a current major depressive 
episode, which we defined according to criteria of the Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition (DSM-IV).
See Online for appendix
For more on R see http://www.r-project.org/
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Statistical analysis
We did all statistical analyses with Stata version 11 (College Station, TX, USA) and R. We 
summarised data as either the number of participants (% or 95% CI), mean (SD), and 
median (IQR). We did bivariate analyses with the χ2 test, Student’s t test, or Wilcoxon’s 
rank-sum test. We used Cohen’s d to calculate the effect size of the differences between 
participants who underwent polysomnography and those who did not. We used logistic 
regression models to assess the association between various demographic and clinical 
variables and both mild-to-severe sleep-disordered breathing (≥5 events per h on the apnoea-
hypopnoea index) and moderate-to-severe sleep-disordered breathing (≥15 per h on the 
apnoea-hypopnoea index), in men and women. To estimate the association between severity 
of sleep-disordered breathing and risk of diabetes, hypertension, metabolic syndrome, and 
depression, we used logistic regression models and divided our sample into quartiles of 
apnoea-hypopnoea index (Q1, 0–4·2 events per h; Q2, 4·3–9·9 events per h; Q3, 10·0–20·6 
per h; Q4, >20·6 events per h). We compared models with the likelihood ratio test.
Role of the funding sources
The Faculty of Biology and Medicine of Lausanne, the Lausanne University Hospital 
(CHUV), Leenaards Foundation, and Ligue Pulmonaire Vaudoise funded the salary of the 
technicians who did the sleep recordings. The Swiss National Science Foundation funded 
the statisticians and supported the initial CoLaus cohort. GlaxoSmithKline supported the 
initial CoLaus cohort and funded the polysomnography recorders. The funders of the study 
had no role in study design, data collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between Sept 1, 2009, and June 30, 2013, a consecutive sample of 3043 people from the 
CoLaus/PsyCoLaus study cohort were invited to undergo polysomnography overnight at 
their home (appendix p 1). Of these, 2168 (71%) individuals accepted the invitation and 
underwent polysomnography. Of the 2168 polysomnographic recordings, 60 (3%) had 
technical problems resulting in insufficient data; 54 participants underwent a second 
recording and six people declined. 41 individuals with a total sleep time less than 4 h were 
excluded because of the risk of an unbalanced representation of different sleep stages and 
positions; therefore, 2121 polysomno-graphic recordings were included in the analysis, and 
these people comprised the HypnoLaus cohort. Table 1 presents demographic and clinical 
characterisitics of the study cohort.
Compared with the whole CoLaus/PsyCoLaus cohort, individuals who underwent 
polysomnography were similar in terms of age, sex, body-mass index (BMI), and ethnic 
origin, and they were representative of Lausanne’s general population.22 However, some 
mild differences were noted between the two cohorts with respect to scores on the Pittsburgh 
sleep quality index, the Epworth sleepiness scale, and the Berlin questionnaire for sleep-
disordered breathing (appendix p 3).
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In the total HypnoLaus Study cohort, hypopnoea was the most common respiratory event 
(75%), followed by obstructive sleep apnoea (19%), central apnoea (4%), and mixed apnoea 
(2%). To assess a possible first-night effect, the first 20 participants underwent two 
consecutive polysomnographic recordings at home. The type and severity of respiratory 
events and sleep quality were similar between the two nights (data not shown).
Figure 1 shows the prevalence of sleep-disordered breathing according to clinically defined 
categories (mild, moderate, and severe) in men and women. An apnoea-hypopnoea index of 
five or more events per h (ie, mild-to-severe sleep-disordered breathing) was recorded in 
858 (83·8%; 95% CI 81·4–86·0) men and 667 (60·8%; 57·8–63·7) women, whereas an 
apnoea-hypopnoea index of 15 or more events per h (moderate-to-severe sleep-disordered 
breathing) was noted in 509 (49·7%; 46·6–52·8) men and 257 (23·4%; 20·9–26·0) women. 
To assess the effect of age on prevalence of sleep-disordered breathing, we divided our 
population into two age categories, younger than 60 years and 60 years or older, which is 
roughly the median age of the total participants. Moderate-to-severe sleep-disordered 
breathing increased significantly in older participants compared with those in the younger 
age group, but this difference in prevalence seems to be less important for sleep apnoea 
syndrome (figure 1).
The main risk factors associated with presence of sleep-disordered breathing were sex, age, 
BMI, neck circumference, waist-to-hip ratio (in women), and snoring (table 2). However, no 
association was noted between severity of sleep-disordered breathing and presence of 
daytime sleepiness, measured with the Epworth sleepiness scale.
Compared with women, scores on the apnoea-hypopnoea index were around three times 
higher in men in the younger age category (≥40 to <60 years) and twice as high in older men 
(≥60 years; table 3). 305 (49%) women younger than 60 years were postmenopausal, and 
this number rose to 490 (100%) in those 60 years or older. Median scores on the apnoea-
hypopnoea index were significantly lower in premenopausal women (2·8 [IQR 1·5–7·5] 
events per h) compared with postmenopausal women (8·7 [4·2–16·9]; p<0·0001). Compared 
with men with moderate-to-severe sleep-disordered breathing, women in this category were 
older (67 years [IQR 57–73] vs 62 years [53–70]; p<0·0001) and had a lower Epworth score 
(mean 5·6 [SD 3·6] vs 6·6 [3·8]; p=0·0005). Men and women in the moderate-to-severe 
category had similar BMI (mean 27·6 kg/m2 [SD 5·1] vs 27·2 kg/m2 [3·7], p=0·24), but 
women had a smaller neck circumference (mean 35·3 cm [SD 2·6] vs 40·6 cm [2·8]; 
p<0·0001) and a lower waist-to-hip ratio (mean 0·90 [SD 0·06] vs 0·97 [0·05]; p<0·0001).
Figure 2 shows the association between severity of sleep-disordered breathing and risk of 
diabetes, hypertension, metabolic syndrome, and depression using four models with 
progressive adjustments. Adjusting for BMI (in model 3) significantly decreased the 
associations between sleep-disordered breathing and diabetes, hypertension, and metabolic 
syndrome. Conversely, adjusting for age and sex revealed an association between depression 
and sleep-disordered breathing in model 2. In the fully adjusted models (model 4), the upper 
quartile of the apnoea-hypopnoea index (Q4, >20·6 events per h) was associated 
independently with the presence of hypertension (odds ratio 1·60, 95% CI 1·14–2·26; 
p=0·0292 for trend across severity quartiles), diabetes (2·00, 1·05–3·99; p=0·0467), 
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metabolic syndrome (2·80, 1·86–4·29; p<0·0001), and depression (1·92, 1·01–3·64; 
p=0·0292). The interaction term BMI × apnoea-hypopnoea index for hypertension 
(p=0·875), diabetes (p=0·490), and metabolic syndrome (p=0·382) was not included in these 
models because they were not significant. Using the apnoea-hypopnoea index as a 
continuous variable in the same fully adjusted regression models led to similar independent 
associations with diabetes (p=0·0119), metabolic syndrome (p<0·0001), hypertension 
(p=0·0098), and depression (p=0·0260).
Discussion
To our knowledge, the HypnoLaus Sleep Cohort study is the largest study to assess the 
prevalence of sleep-disordered breathing in a population-based sample using the most recent 
polysomnographic recording techniques and scoring criteria. We recorded a much higher 
than previously estimated prevalence of sleep-disordered breathing and an independent 
association between the disorder and diabetes, hypertension, metabolic syndrome, and 
depression, albeit mainly in the highest severity quartile of the apnoea-hypopnoea index 
(>20·6 events per h).
The first report of prevalence of sleep-disordered breathing was published 20 years ago by 
Young and colleagues10 and was based on the Wisconsin Cohort Study (WSCS). In a 
follow-up of WSCS, increased prevalence estimates were reported.13 However, the earlier 
study was not strictly population-based because it included an enriched selection of people 
at risk for sleep-disordered breathing (panel). The reported prevalence of sleep-disordered 
breathing was, thus, estimated using models extrapolating the observed results to the general 
US population using demographic data from the National Health and Nutrition Examination 
Survey (NHANES) study.
The high prevalence of sleep-disordered breathing recorded in our cohort could be 
accounted for by two factors. First, we measured the prevalence of sleep-disordered 
breathing directly in the general population rather than estimating it; and second, we used 
currently recommended techniques (including nasal pressure sensors) and scoring criteria. 
To date, only two studies based directly on samples from the general population have been 
done.17,18 In both studies, researchers reported a high prevalence of sleep-disordered 
breathing. In a study from Spain of 2148 individuals aged 30–70 years,18 the prevalence of 
sleep-disordered breathing (apnoea-hypopnoea index >5 events per h) was 26·2% in men 
and 28·0% in women. However, full polysomnography was only used in a subset of 390 
participants, and most participants were studied with limited channels recorders without 
direct airflow measurement, which does not match current standards.21 In a study from 
Brazil of 1042 participants aged 20–80 years,17 the latest breathing sensors were used to 
measure variation in nasal pressure (which is the technique currently used in all modern 
clinical laboratories). The researchers reported a high prevalence of sleep-disordered 
breathing (apnoea-hypopnoea index >5 events per h) of 46·6% in men and 30·5% in women; 
however, these results were obtained in a specific mixed ethnic population and are difficult 
to generalise to other populations.
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The findings of these studies and ours suggest that the prevalence of sleep-disordered 
breathing is highly dependent on technical factors. Nasal pressure sensors detect subtle 
breathing variations, resulting in detection of more hypopnoea events (and, therefore, a 
higher apnoea-hypopnoea index) than with thermistors, which have decreased sensitivity 
(appendix p 2).27,28 The 2012 AASM criteria21 propose a more liberal definition of 
hypopnoea, whereas more strict definitions were used in previous studies. Although this 
change in definition might partly account for the increased prevalence of sleep-disordered 
breathing in our study, prevalence was still higher than previously reported after rescoring 
the polysomnographic recordings using the older and more restrictive criteria (appendix p 
4).
In our study, clinical and epidemiological factors associated with sleep-disordered breathing 
were increasing age, male sex, large neck circum ference, obesity, and reported snoring, 
similar to previous studies.10,12,29 The difference in prevalence of sleep-disordered 
breathing between men and women seemed to diminish in participants aged 60 years or 
older, probably because of the increased proportion of postmenopausal women in this age 
category, who had a higher median apnoea-hypopnoea index compared with premenopausal 
women. Even though women and men with an apnoea-hypopnoea index of 15 or more 
events per h had a similar BMI, women had a lower neck circumference and waist-to-hip 
ratio compared with men. This finding confirms that not only central obesity but also 
hormonal status affects the prevalence of sleep-disordered breathing in women.
Independent associations between severity of sleep-disordered breathing and diabetes, 
hypertension, metabolic syndrome, and depression were noted after multivariable 
adjustment. This finding suggests that we identified a clinically important disease rather than 
simply over-diagnosing healthy individuals. These results accord with findings of the 
WSCS,2 in which sleep-disordered breathing was associated prospectively with 
hypertension, a result confirmed by later observational and interventional studies.30,31 
Moreover, a prospective association with depression has been reported previously.8 Diabetes 
seems to have a bidirectional association with sleep-disordered breathing: intermittent 
hypoxaemia contributes to development of insulin resistance and glucose intolerance, and 
type 2 diabetes increases an individual’s predisposition to sleep-disordered breathing.9,32,33 
However, fewer reports have been published of an association between sleep-disordered 
breathing and metabolic syndrome.34
In previous studies, even sleep-disordered breathing of the lowest severity (apnoea-
hypopnoea index >5 events per h) was associated with hypertension2,18 or depression.8 
However, we noted these associations mostly in the upper quartile of severity (apnoea-
hypopnoea index >20·6 events per h). Since current recording techniques and scoring 
criteria are more sensitive than those used previously, this finding strongly suggests that the 
definition of sleep-disordered breathing should be revised. Indeed, in our study, almost 
every individual had some degree of sleep-disordered breathing, and an increasing apnoea-
hypopnoea index was associated with augmented prevalence of comorbid diseases. These 
results reinforce the idea that, instead of using the arbitrary diagnostic threshold of the 
apnoea-hypopnoea index, sleep-disordered breathing should be considered as a disease 
characterised by a severity spectrum, akin to blood pressure or cholesterol levels. Treatment 
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of sleep-disordered breathing should, thus, be increasingly aggressive with rising apnoea-
hypopnoea index, particularly in individuals with risk factors for comorbidities associated 
with sleep-disordered breathing, such as sleepiness, cardiovascular disease, metabolic 
disease, and depression. Treatments will ultimately be guided by appropriately designed 
clinical trials, but individuals with a low apnoea-hypopnoea index and at low risk for 
comorbidities could be treated conservatively to reduce risk factors for sleep-disordered 
breathing (eg, weight control or avoiding sleep in the supine position), whereas individuals 
at higher risk could benefit from continuous positive airway pressure (CPAP), mandibular 
advancement devices, and surgery (eg, maxillomandibular advancement surgery) in selected 
cases. This rational approach to sleep-disordered breathing is implemented de facto by 
skilled clinicians; however, our results emphasise the importance of dedicating health care 
resources to individuals at high risk of complications rather than initiating treatment based 
on an apnoea-hypopnoea index threshold. Ultimately, follow-up of the HypnoLaus cohort 
will allow us to identify individuals at high risk of incident complications (eg, using 
biological or genetic markers) and will help to provide therapeutic recommendations in an 
individualised manner.
The major strengths of our study are that it was done in a large, population-based sample, 
enabling extrapolation of findings to the original population. Moreover, poly somnographic 
recordings were done in the participant’s home environment, thus minimising the likelihood 
of information bias. Finally, modern recording techniques and scoring criteria were applied, 
which ensures validity of results in view of current recommendations.21
The main limitations of our study are the cross-sectional setting and the inclusion of 
individuals aged 40–85 years old only, almost exclusively of white European origin and 
with a low prevalence of obesity. Thus, generalisation of findings to younger people, to 
populations with a high prevalence of obesity, or to people from other ethnic backgrounds is 
limited. For example, the average BMI is lower in Switzerland than in the USA, suggesting 
that the prevalence of sleep-disordered breathing could be higher in a North American 
population. Second, 29% of participants declined to have polysomnography, which might 
have caused selection bias. However, since the HypnoLaus sample was similar in terms of 
age, sex, BMI, and ethnic origin to the CoLaus/PsyCoLaus cohort, which is representative of 
Lausanne’s general population, we believe that our results are probably very close to the true 
prevalence of sleep-disordered breathing in the general population. Finally, a variable time 
gap existed between clinical assessment of participants and polysomnography, but it 
probably did not affect the association between severity of sleep-disordered breathing and 
diabetes, hypertension, metabolic syndrome, and depression, since these disorders are 
typically chronic conditions.
The prevalence of sleep-disordered breathing in the general population is considerably 
higher than previously reported when the most recent recording techniques and scoring 
criteria are used. Caution is thus needed when comparing the prevalence of sleep-disordered 
breathing with previous studies in which different sampling frames, recording techniques, 
and scoring criteria were used. These results, and the progressive association between 
severity of sleep-disordered breathing and cardiovascular, metabolic, and psychiatric 
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diseases, suggest that an arbitrary threshold for the apnoea-hypopnoea index could be hard 
to define and clinical decisions might need a complete clinical picture to be well informed.
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Panel: Research in context
Systematic review
We searched PubMed up to October, 2014, with the terms “sleep apnea”, “sleep apnoea”, 
or “sleep disordered breathing”, and “prevalence”. After exclusion of studies that did not 
include objective nocturnal measurements, we retrieved 21 epidemiological studies 
assessing the prevalence of sleep-disordered breathing in different populations. Results of 
epidemiological studies done in the late 1980s and 1990s showed a rather low prevalence 
of sleep-disordered breathing, probably due to low sensitivity of recording 
techniques.10,12 These and almost all subsequent studies included population samples 
selected or enriched with individuals presenting risk factors for sleep-disordered 
breathing or cardiovascular disease, and were thus not representative of the general 
population. Therefore, statistical corrections were needed to estimate the prevalence of 
sleep-disordered breathing in the general population in those studies. Another important 
factor affecting prevalence of sleep-disordered breathing is the definition of respiratory 
events, which strongly affects the apnoea-hypopnoea index (appendix p 4). Since these 
definitions were updated in 2012, none of the previous epidemiological studies could use 
the up-to-date definition of respiratory events.
Interpretation
Using the most recent definitions for respiratory events, and diagnostic techniques 
commonly used in all modern sleep laboratories, we noted that almost every individual 
had some degree of sleep-disordered breathing. Moreover, an increasing number of 
apnoea and hypopnoea events per h was associated with augmented comorbidity. This 
finding reinforces the idea that sleep-disordered breathing should be considered as a 
disease with a continuous spectrum, rather than as a definite yes or no diagnosis. 
Individuals at high risk of incident sleep-disordered breathing-related complications 
should be identified so treatment efforts can be focused on them.
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Figure 1. Prevalence of sleep-disordered breathing and sleep apnoea syndrome, according to age 
and sex
(A) Mild sleep-disordered breathing was defined as ≥5 to <15 events per h, moderate was 
≥15 to <30 events per h, and severe was ≥30 events per h. Sleep-disordered breathing 
categories differed by age; p<0·0001 in men and p<0·0001 in women. (B) Mild sleep apnoea 
syndrome was defined as ≥5 to <15 events per h and an Epworth score >10, moderate was 
≥15 to <30 events per h and an Epworth score >10, and severe was ≥30 events per h and an 
Epworth score >10. Categories of sleep apnoea syndrome differed by age; p<0·0001 in men 
and p<0·0001 in women.
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Figure 2. Estimated risk for diabetes, metabolic syndrome, hypertension, and depression 
associated with severity of sleep-disordered breathing
Circles represent the odds ratio and bars the 95% CI. If bars cross the dotted line at 1·0, risk 
is not significant. Apnoea-hypopnoea index severity quartiles are defined as: Q1, 0–4·2 
events per h; Q2, 4·3–9·9 events per h; Q3, 10·0–20·6 events per h; and Q4, >20·6 events per 
h. p values are for trend across severity quartiles. For diabetes, metabolic syndrome, and 
hypertension: model 1 was adjusted for age and sex; model 2 was adjusted for age, sex, and 
alcohol and tobacco consumption; model 3 was adjusted for age, sex, alcohol and tobacco 
consumption, and BMI; and model 4 was adjusted for age, sex, alcohol and tobacco 
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consumption, BMI, neck circumference, and waist-to-hip ratio (except for metabolic 
syndrome because this ratio is part of its definition). For depression: model 1 was raw data; 
model 2 was adjusted for age and sex; model 3 was adjusted for age, sex, and use of 
benzodiazepines; and model 4 was adjusted for age, sex, use of benzodiazepines, and use of 
antidepressant drugs.
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Table 1
Demographic and clinical characteristics of participants
Total (n=2121) Men (n=1024) Women (n=1097) p value*
Age (years) 57 (49–68) 56 (49–67) 58 (50–69) 0·0263
  ≥40 to <60 1219 (57%) 613 (60%) 606 (55%) ..
  ≥60 902 (43%) 411 (40%) 491 (45%) ..
BMI (kg/m2) 25·6 (4·1) 26·2 (3·7) 25·1 (4·6) <0·0001
Neck circumference (cm) 36·9 (3·9) 39·8 (2·8) 34·1 (2·4) <0·0001
Waist-to-hip ratio 0·92 (0·07) 0·96 (0·06) 0·88 (0·06) <0·0001
Alcohol use 560 (26%) 325 (32%) 235 (21%) <0·0001
Smoking 1210 (57%) 654 (64%) 556 (51%) <0·0001
Snoring 1164 (55%) 678 (66%) 486 (44%) <0·0001
Hypertension 877 (41%) 497 (49%) 380 (35%) <0·0001
Diabetes 212 (10%) 145 (14·%) 67 (6%) <0·0001
Metabolic syndrome 641 (30%) 366 (36%) 275 (25%) <0·0001
Epworth score 6 (3–9) 6 (4–9) 5 (3–8) <0·0001
  >10 258 (12%) 143 (14%) 115 (10%) 0·0129
PSQI score 4 (3–7) 4 (3–6) 5 (3–7) <0·0001
Berlin score ≥2 525 (25%) 315 (31%) 210 (19%) <0·0001
Data are number of participants (%), median (IQR), or mean (SD). BMI=body-mass index. PSQI=Pittsburgh sleep quality index.
*Comparison between men and women.
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Table 3
Scores on the apnoea-hypopnoea index and oxygen desaturation index, by sex and age
Total Men Women p value*
Apnoea-hypopnoea index (events per h)
Total 9·9 (4·2–20·6) 14·9 (7·2–27·1) 6·9 (2·7–14·1) <0·0001
  Age ≥40 to <60 years 7·6 (2·9–15·9) 11·7 (6·1–21·1) 4·3 (1·9–9·3) <0·0001
  Age ≥60 years 14·3 (7·0–27·2) 21·1 (9·4–35·6) 10·8 (5·5–20·0) <0·0001
  p value† <0·0001 <0·0001 <0·0001 ..
3% oxygen desaturation index (events per h)
Total 9·9 (4·3–19·4) 14·4 (6·9–24·9) 6·9 (2·9–13·5) <0·0001
  Age ≥40 to <60 years 7·3 (3·2–15·0) 11·4 (5·9–20·0) 4·4 (1·9–9·3) <0·0001
  Age ≥60 years 13·8 (7·0–26·1) 19·5 (9·9–32·8) 11·0 (5·4–19·5) <0·0001
  p value† <0·0001 <0·0001 <0·0001 ..
4% oxygen desaturation index (events per h)
Total 4·0 (1·2–10·1) 6·4 (2·3–14·25) 2·4 (0·7–6·5) <0·0001
  Age ≥40 to <60 years 2·7 (0·7–6·9) 4·7 (1·6–10·6) 1·3 (0·3–3·9) <0·0001
  Age ≥60 years 6·6 (2·5–15·6) 9·9 (3·9–21·1) 4·9 (1·9–10·3) <0·0001
  p value† <0·0001 <0·0001 <0·0001 ..
Data are median scores (IQR). The apnoea-hypopnoea index is defined as the number of apnoea and hypopnoea events per h. The oxygen 
desaturation index is defined as the number of 3% or 4% drops in oxygen saturation per h of sleep. p values calculated by Wilcoxon’s rank-sum 
tests.
*Comparison between men and women.
†Comparison between age groups.
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